January 10, 2019
Ono Pharmaceutical said on January 9 its anti-PD-1 antibody Opdivo (nivolumab) demonstrated a statistically significant extension in overall survival (OS) versus chemotherapy in a PIII study examining the drug as a second-line treatment for esophageal cancer. The global multi-center, randomized,...read more